<DOC>
	<DOCNO>NCT02214381</DOCNO>
	<brief_summary>Comparison pre-surgical Myocet/ Cyclophosphamide ( MC ) q3w follow either MC Paclitaxel - depend early response assessment ultrasound toxicity elderly non frail primary breast cancer patient increase risk relapse .</brief_summary>
	<brief_title>A Prospective , Multicenter , Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy Elderly Patients With Low Response</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>General Inclusion Criteria ADAPT : Female patient , age diagnosis 18 year ( consider patient 70 year ADAPT Elderly ) Candidate chemotherapy basis conventional criterion Histologically confirm unilateral primary invasive carcinoma breast Clinical T1 T4ac All clinical N ( cN ) No clinical evidence distant metastasis ( M0 ) Known HR status HER2 status ( local pathology ) Tumor block available central pathology review Performance Status ECOG &lt; = 1 KI &gt; = 80 % Written inform consent prior begin specific protocol procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement The patient must accessible treatment followup Patients must qualify neoadjuvant treatment LVEF &gt; 50 % ; LVEF within normal limit institution measure echocardiography normal ECG ( within 42 day prior chemotherapy ) Laboratory requirement : Leucocytes ≥ 3.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥ 10 g/dL Total bilirubin ≤ 1 x ULN ASAT ( SGOT ) ALAT ( SGPT ) ≤ 2.5 x UNL Creatinine ≤ 175 µmol/L ( 2 mg/dl ) Additional inclusion criterion ADAPT Elderly : ≥ 70 year old Charlson scale ≤ 2 HR+/HER2 disease : RS sequential test available N01/RS 1225/poor response N01/RS ≥26 All G3 Ki67 ≥40 % tumor &gt; 1cm All N2 All TN All subtypes General Exclusion Criteria ADAPT : Known hypersensitivity reaction compound incorporated substance Prior malignancy diseasefree survival &lt; 10 year , except curatively treat basalioma skin , pTis cervix uteri Nonoperable breast cancer include inflammatory breast cancer Previous concurrent treatment cytotoxic agent reason consultation sponsor Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry ( concurrent participation noninterventional post authorization safety study influence primary study endpoint allow , e.g . WSG PROTROCA evaluation primary/secondary GCSF prophylaxis ) Male breast cancer Sequential breast cancer Reasons indicate risk poor compliance Patient able consent Additional Exclusion Criteria ADAPT Elderly : Known polyneuropathy ≥ grade 2 Severe relevant comorbidity would interact application cytotoxic agent participation study Inadequate organ function ( e.g . hepatic impairment , pulmonary disease , etc . ) Uncompensated cardiac function ( current unstable ventricular arrhythmia require treatment , history symptomatic CHF NYHA class IIIV ) , history myocardial infarction unstable angina pectoris within 12 month enrollment , history severe hypertension , CAD coronary artery disease ) Severe dyspnea Pneumonitis Abnormal blood value : Thrombocytopenia &gt; CTCAE grade 1 Increases ALT/AST &gt; CTCAE grade 1 Hypokalaemia &gt; CTCAE grade 1 Neutropenia &gt; CTCAE grade 1 Anaemia &gt; CTCAE grade 1</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>elderly</keyword>
</DOC>